On Jan. 28, 2020, Alexion Pharma announced it had completed its acquisition of Achillion Pharmaceuticals for $930 million.

The acquisition added two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases.